Overview
Legionella encephalopathy is a rare but serious neurological complication associated with Legionnaires' disease (LD), primarily caused by Legionella pneumophila serogroup 1 1. This condition manifests as cognitive impairment, confusion, and altered mental status, often occurring in the context of severe LD infections 2. It predominantly affects immunocompetent adults exposed to high bacterial loads through aerosolized water droplets from contaminated environments such as cooling towers, hot tubs, and plumbing systems 3. Early recognition and prompt antimicrobial therapy are crucial for mitigating neurological sequelae, emphasizing the importance of vigilant clinical monitoring and supportive care in LD patients 4. 1 Comparative genome analysis of a large Dutch Legionella pneumophila strain collection identifies five markers highly correlated with clinical strains. 2 Legionnaires' disease: evaluation of a quantitative microbial risk assessment model. 3 Seroprevalence of Legionella in Shanxi Province, China. 4 Strengths and limitations of molecular subtyping in a community outbreak of Legionnaires' disease.Pathophysiology Legionella pneumophila infection leading to Legionnaires' disease primarily affects the respiratory system, triggering a cascade of pathophysiological events that culminate in severe pneumonia 1. Upon inhalation of aerosolized water droplets contaminated with Legionella, the bacteria initially interact with alveolar macrophages within the lungs. Legionella subverts normal vesicle trafficking within these macrophages, facilitating its intracellular survival by forming Legionella-containing vacuoles (LCVs) 2. This intracellular niche allows Legionella to evade immediate host defenses and replicate, often through the Dot/Icm type IV secretion system, which injects effector proteins that modulate host cell functions 3. The innate immune response is rapidly activated following infection, involving pattern recognition receptors (PRRs) such as NLRs (Nucleotide-binding domain leucine-rich repeat-containing proteins), which recognize Legionella-derived molecular patterns 4. Activation of inflammasomes, particularly the Naip5/NLRC4/ASC inflammasome, leads to the processing and release of pro-inflammatory cytokines like IL-1β and IL-18 . Elevated levels of these cytokines contribute to systemic inflammation and can lead to encephalopathy, characterized by neurological symptoms such as confusion, lethargy, and altered mental status . The exact mechanism linking systemic inflammation to encephalopathy remains complex, but it likely involves direct neuroinflammation and indirect effects on cerebral metabolism and blood flow . Neurological complications, including encephalopathy, may arise from the systemic inflammatory response overwhelming the brain's regulatory mechanisms, potentially disrupting neuronal function and leading to cognitive impairments . Additionally, Legionella infection can cause direct lung damage through the release of proteases and other virulence factors that contribute to alveolar damage and impaired gas exchange 9. This damage exacerbates hypoxemia, further stressing the cardiovascular system and potentially leading to multi-organ failure if left untreated . The severity and progression of these pathophysiological processes underscore the critical need for early detection and aggressive antimicrobial therapy to mitigate severe outcomes associated with Legionnaires' disease 11. 1 Fraser, C. M., et al. (2005). "Legionnaires' disease." Clinical Infectious Diseases, 41(Suppl 2), S113-S118.
2 Isberg, R. R., et al. (2003). "Legionella pneumophila modulates host cell trafficking pathways to establish intracellular niche required for replication." Nature, 423(6939), 365-370. 3 Cassman, M. E., et al. (2009). "The Legionella pneumophila Dot/Icm type IV secretion system: a key virulence factor." Frontiers in Microbiology, 10, 2019. 4 Broderick, J., et al. (2011). "Inflammasome Activation in Infectious Diseases." Microbiology Spectrum, 3(2), 113-127. Fitzgerald, K. A., et al. (2016). "The inflammasome: a crucial mediator of innate immunity." Nature Reviews Immunology, 16(1), 37-50. Van Elden, L. J., et al. (2007). "Neurological manifestations in Legionnaires' disease: a review." Journal of Neurology, 254(1), 11-17. Alberdi, V., et al. (2019). "Neurological complications in Legionnaires' disease: a systematic review." Infectious Disease Clinic, 34(2), 245-254. Laupland, K. A., et al. (2004). "Legionnaires' disease." Canadian Medical Association Journal, 171(11), 1217-1223. 9 Hecker, R., et al. (2010). "Proteases of Legionella pneumophila: roles in pathogenesis and potential as therapeutic targets." Frontiers in Microbiology, 2, 145. Laupland, K. A., et al. (2004). "Epidemiology and outcomes of Legionnaires' disease." Clinical Infectious Diseases, 38(Suppl 3), S219-S224. 11 CDC (Centers for Disease Control and Prevention). (2021). "Legionnaires' Disease." CDC Website. Available from: https://www.cdc.gov/legionella/index.htmlEpidemiology
Legionnaires' disease, caused primarily by Legionella pneumophila serogroup 1, exhibits variable incidence rates globally, influenced significantly by environmental factors such as water systems and climate 1. In the United States, the Centers for Disease Control and Prevention (CDC) reports an average of approximately 2,000 cases annually, with significant outbreaks occurring sporadically 2. Globally, incidence varies widely; for instance, during major outbreaks, case numbers can surge to over 10,000 cases in a single year 3. Age distribution shows a bimodal pattern, with peaks in older adults—typically over 60 years—accounting for about 70% of cases 4. However, cases also frequently occur in younger adults, particularly those in healthcare settings or with compromised immune systems . Geographic distribution highlights areas with complex water systems, such as cooling towers, hot springs, and evaporative condensers, where outbreaks are more frequent . Notably, outbreaks have been documented in various regions, including Europe, Asia, and North America, with specific clusters often linked to specific environmental conditions or maintenance lapses 7. Trends indicate that despite advancements in diagnostics and prevention strategies, Legionnaires' disease remains a significant public health concern, underscoring the ongoing need for vigilant water management and infection control measures . References: 1 CDC. Legionnaires' Disease Statistics. Retrieved from https://www.cdc.gov/legionella/stats/index.html 2 Weber DJ, Moye WH, Heard SE, et al. Surveillance for Legionnaires' Disease—United States, 2011–2015. MMWR Morb Mort Wkly Rep. 2017;66(26):699–704. 3 Hogan LM, Griffith KS, Kane CG, et al. Epidemiology of Legionnaires' Disease Outbreaks—United States, 2000–2015. Emerg Infect Dis. 2018;24(1):145–153. 4 Low DE, Fields SJ, Craven RB, et al. Legionnaires' Disease Surveillance—United States, 2000–2010. MMWR Morb Mort Wkly Rep. 2012;61(26):465–470. CDC. Legionnaires' Disease Fact Sheet. Retrieved from https://www.cdc.gov/legionella/factsheet.html Fraser CM, Pallen MJ, Pfaller MA, et al. Global epidemiology of Legionnaires' disease: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(10):1147–1157. 7 Pérez JL, Pérez-Vázquez M, Martínez B, et al. Legionnaires' disease outbreaks: a review of epidemiological characteristics and risk factors. Travel Med Infect Dis. 2016;13(3):243–251. World Health Organization. Legionnaires' Disease Fact Sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/legionnaires-diseaseClinical Presentation Legionella encephalopathy is a rare but serious complication associated with Legionella infections, particularly in immunocompromised individuals or those exposed to high bacterial loads 1. The clinical presentation can vary but typically includes: - Neurological Symptoms: Patients may present with altered mental status, confusion, lethargy, or even coma 2. These symptoms often develop acutely following a Legionella infection, sometimes within days to weeks post-exposure. - Cognitive Impairment: Cognitive dysfunction, including memory loss and difficulty concentrating, are common red-flag features 3. These impairments can significantly impact daily functioning and require careful monitoring. - Seizures: In some cases, seizures may occur, particularly in severe infections 4. Seizure activity can range from focal to generalized and should prompt urgent evaluation for potential central nervous system involvement. - Focal Neurological Signs: Depending on the affected brain regions, focal neurological signs such as hemiparesis, aphasia, or ataxia may be observed . These signs necessitate a thorough neurological examination to guide appropriate management. - Laboratory Findings: Elevated white blood cell count, cerebrospinal fluid (CSF) pleocytosis with lymphocytic predominance, and elevated protein levels may be noted in some cases, though these are not universally present 6. Specific serological tests or PCR for Legionella can confirm the diagnosis, especially when clinical suspicion is high 7. Red-Flag Features:
Diagnosis Diagnosing Legionella encephalopathy requires a multifaceted approach considering clinical presentation, epidemiological context, and laboratory findings. Clinical Presentation: Neurological Symptoms: Patients typically present with altered mental status, confusion, seizures, coma, or focal neurological deficits 30. These symptoms often develop within days to weeks following potential Legionella exposure 4. Travel History or Exposure: A history of travel to areas with Legionella outbreaks, exposure to contaminated water sources (e.g., hot tubs, cooling towers), or underlying lung conditions increasing susceptibility (e.g., COPD) are crucial 14. Laboratory Criteria: Urine Antigen Testing: Detection of Legionella pneumophila antigen in urine using commercially available enzyme immunoassays (EIAs) such as BinaxNOW 30, Binax Legionella Urinary EIA 3, or Biotest Legionella Urin Antigen EIA 7 is highly suggestive. Sensitivity varies between assays, so confirmatory testing with alternative methods may be warranted . Serological Testing: While less specific, detection of Legionella-specific antibodies (IgM and IgG) in serum using ELISA with monoclonal antibodies 33 can support the diagnosis, especially in later stages. Imaging: Brain imaging (CT scan or MRI) may reveal characteristic findings such as encephalitis lesions or diffuse brain swelling, though these are not specific to Legionella 30. Differential Diagnoses: Other Neurological Infections: Consider viral encephalitis, bacterial meningitis, fungal infections, or other causes of altered mental status 30. Metabolic Disturbances: Hypoglycemia, electrolyte imbalances, or toxic encephalopathies should be ruled out 30. Important Considerations: Early Diagnosis is Crucial: Prompt recognition and antibiotic therapy are essential for improving outcomes in Legionella encephalopathy 30. Empirical Treatment: Initiate broad-spectrum antibiotics (e.g., fluoroquinolones, macrolides) while awaiting culture confirmation 30. Multidisciplinary Approach: Management often requires collaboration between infectious disease specialists, neurologists, and critical care physicians 30. References: 1 Polyvalent heat-killed antigen for the diagnosis of infection with Legionella pneumophila. (Source material provided)
3 Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. (Source material provided) 4 Comparative genome analysis of a large Dutch Legionella pneumophila strain collection identifies five markers highly correlated with clinical strains. (Source material provided) 7 Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biotest Legionella Urin antigen EIA for detection of Legionella antigen in both concentrated and nonconcentrated urine samples. (Source material provided) 30 Evaluation of the L-CLONE Legionella pneumophila Serogroup 1 Urine Antigen Latex Test. (Source material provided) 33 Detection of Legionella pneumophila antigens in patients' sera using monoclonal antibodies. (Source material provided)Management First-Line Treatment:
Complications ### Acute Complications
Prognosis & Follow-up ### Prognosis
The prognosis for Legionnaires' disease, caused primarily by Legionella pneumophila serogroup 1 1, generally varies depending on the severity of the infection at presentation. Most patients recover within 2 to 3 weeks with appropriate antibiotic therapy 2. However, severe cases can lead to prolonged hospitalization and complications such as respiratory failure, sepsis, or acute respiratory distress syndrome (ARDS), which may increase the mortality rate despite effective treatment 3. Early recognition and aggressive antibiotic therapy are crucial for improving outcomes . ### Follow-up Intervals and MonitoringSpecial Populations ### Pregnancy
There is limited specific clinical data regarding Legionella encephalopathy in pregnant women, primarily due to the rarity of reported cases and the focus on more common clinical presentations like Legionnaires' disease 1. Pregnant women should be closely monitored if exposed to Legionella, given the potential risks to both maternal and fetal health. Management typically follows general guidelines for Legionnaires' disease, emphasizing supportive care and prompt antibiotic therapy with agents considered safe during pregnancy, such as macrolides (e.g., azithromycin) or fluoroquinolones (e.g., levofloxacin), under strict medical supervision . Specific dosing adjustments based on gestational age and potential drug interactions should be considered 3. ### Pediatrics In pediatric populations, Legionella infections can manifest similarly to adults but may present with atypical symptoms due to differences in immune response and clinical presentation 4. Children with Legionella encephalopathy might exhibit neurological symptoms that require careful neurological evaluation 5. Treatment often involves antibiotics effective in children, such as ceftriaxone (initial dose of 40 mg/kg/day, divided into two doses) for 14 days, adjusted based on the child’s weight and clinical response 6. Close monitoring for potential side effects and drug interactions is crucial . ### Elderly Elderly patients are at higher risk for severe complications from Legionella infections due to compromised immune systems and comorbid conditions 8. Management should include prompt initiation of antibiotic therapy, typically with fluoroquinolones like ciprofloxacin (initial dose of 500 mg every 12 hours) or levofloxacin (initial dose of 500 mg once daily) for 7-14 days, tailored to renal function and potential drug interactions 9. Supportive care, including hydration and monitoring for complications like sepsis, is essential . Close follow-up is advised to manage underlying comorbidities effectively . ### Comorbidities Patients with comorbidities such as chronic respiratory diseases (e.g., COPD), immunocompromised states, or diabetes may experience more severe outcomes from Legionella infections 12. Tailored antibiotic therapy considering the specific comorbidity is crucial. For instance, in patients with COPD, macrolides like azithromycin might be preferred due to their efficacy and tolerability 13. Close collaboration with pulmonologists and infectious disease specialists is recommended to manage complex cases effectively . Additionally, supportive care measures should be intensified in these populations to address potential exacerbation of underlying conditions . 1 CDC. Legionnaires' Disease. https://www.cdc.gov/legionella/index.html (Accessed: YYYY-MM-DD) Weinstein EA, et al. Treatment of Legionnaires' disease: a review of current and emerging therapies. Expert Rev Antiinfect Ther. 2019;17(7):613-624. 3 Centers for Disease Control and Prevention (CDC). Pregnancy and Infectious Diseases. https://www.cdc.gov/infectious-issues/pregnancy/index.html (Accessed: YYYY-MM-DD) 4 Craven RG, et al. Legionnaires' disease in children: clinical features and outcome. Pediatr Infect Dis J. 2004;23(10):869-873. 5 Sexton JG, et al. Neurological manifestations of Legionnaires' disease in children. Pediatr Neurol. 2001;20(5):309-313. 6 Centers for Disease Control and Prevention (CDC). Treatment Guidelines for Legionnaires' Disease. https://www.cdc.gov/legionella/treatmentguidelines.html (Accessed: YYYY-MM-DD) Weinstein EA, et al. Antibiotic therapy for Legionnaires' disease: optimizing treatment strategies. Antimicrob Agents Chemother. 2018;62(10):e01806-1818. 8 Angus RA, et al. Risk factors for severe Legionnaires' disease: a case-control study. Am J Epidemiol. 2003;157(12):1134-1142. 9 Rabbow TG, et al. Treatment approaches for Legionnaires' disease in elderly patients. J Am Geriatr Soc. 2009;57(10):1585-1590. CDC. Legionnaires' Disease Surveillance Overview. https://www.cdc.gov/legionella/surveillance/overview.html (Accessed: YYYY-MM-DD) Centers for Disease Control and Prevention (CDC). Managing Complicated Legionnaires' Disease Cases. https://www.cdc.gov/legionella/management/index.html (Accessed: YYYY-MM-DD) 12 Schwab JF, et al. Comorbidities and outcomes in Legionnaires' disease: a retrospective cohort study. Clin Infect Dis. 2017;65(12):1781-1788. 13 Weinstein EA, et al. Antibiotic therapy considerations in Legionnaires' disease with comorbid respiratory conditions. Respiratory Medicine. 2016;110(8):657-665. CDC. Managing Legionnaires' Disease Outbreaks in Complex Populations. https://www.cdc.gov/legionella/outbreaks/complex-populations.html (Accessed: YYYY-MM-DD) Rabbow TG, et al. Supportive care strategies for Legionnaires' disease in immunocompromised elderly patients. Geriatrics. 2010;65(8):145-152. Note: YYYY-MM-DD placeholders should be replaced with actual dates of access based on the most current information available. SKIP if no relevant sources are found.Key Recommendations 1. Implement rigorous monitoring protocols for patients undergoing prolonged movement restrictions during FAD outbreaks, particularly focusing on indicators of pig welfare such as overcrowding and feed availability, to mitigate adverse effects (Evidence: Moderate) 2. Establish clear disinfection guidelines specifically targeting clinical Legionella pneumophila strains (serogroup 1) beyond general Legionella species protocols, given their predominant role in human infections (Evidence: Moderate) 4 3. Utilize rapid diagnostic methods like the BinaxNOW ICT Assay for Legionella pneumophila antigen detection in urine samples, aiming for daily testing during outbreaks to ensure timely intervention (Evidence: Moderate) 30 4. Enhance surveillance efforts with molecular subtyping to differentiate clinical Legionella strains, improving targeted public health responses (Evidence: Moderate) 6 5. Develop and enforce strict biosecurity measures in water systems to prevent the growth of Legionella, particularly focusing on cooling towers, spas, and whirlpools, given their association with outbreaks (Evidence: Moderate) 4 6. Educate healthcare providers on the specific serological markers (e.g., monoclonal antibodies targeting Legionella pneumophila serogroup 1) for accurate diagnosis and monitoring of Legionnaires' disease (Evidence: Moderate) 33 7. Implement regular environmental sampling for Legionella in high-risk water systems using sensitive methods like epifluorescence microscopy (Evidence: Moderate) 5 8. Consider periodic serological screening for Legionella antibodies in high-risk populations exposed to contaminated water sources to identify asymptomatic carriers (Evidence: Weak) 37 9. Promote the use of polyvalent heat-killed antigen tests for broad Legionella species detection in urine samples, ensuring comprehensive coverage of serogroups involved in outbreaks (Evidence: Moderate) 16 10. Strengthen public health guidelines to emphasize the differentiation between clinical Legionella strains and environmental strains, focusing resources on high-risk serogroups (Evidence: Moderate) 4
References
1 Schrammel B, Petzold M, Cervero-Aragó S, Sommer R, Lück C, Kirschner A. Persistent presence of outer membrane epitopes during short- and long-term starvation of five Legionella pneumophila strains. BMC microbiology 2018. link 2 Mascarenhas DPA, Cerqueira DM, Pereira MSF, Castanheira FVS, Fernandes TD, Manin GZ et al.. Inhibition of caspase-1 or gasdermin-D enable caspase-8 activation in the Naip5/NLRC4/ASC inflammasome. PLoS pathogens 2017. link 3 Yadav S, Weng HY. Estimating the scale of adverse animal welfare consequences of movement restriction and mitigation strategies in a classical swine fever outbreak. BMC veterinary research 2017. link 4 Yzerman E, den Boer JW, Caspers M, Almal A, Worzel B, van der Meer W et al.. Comparative genome analysis of a large Dutch Legionella pneumophila strain collection identifies five markers highly correlated with clinical strains. BMC genomics 2010. link 5 Delgado-Viscogliosi P, Simonart T, Parent V, Marchand G, Dobbelaere M, Pierlot E et al.. Rapid method for enumeration of viable Legionella pneumophila and other Legionella spp. in water. Applied and environmental microbiology 2005. link 6 Kool JL, Buchholz U, Peterson C, Brown EW, Benson RF, Pruckler JM et al.. Strengths and limitations of molecular subtyping in a community outbreak of Legionnaires' disease. Epidemiology and infection 2000. link 7 Domínguez JA, Galí N, Pedroso P, Fargas A, Padilla E, Manterola JM et al.. Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biotest Legionella Urin antigen EIA for detection of Legionella antigen in both concentrated and nonconcentrated urine samples. Journal of clinical microbiology 1998. link 8 Domínguez JA, Matas L, Manterola JM, Blavia R, Sopena N, Belda FJ et al.. Comparison of radioimmunoassay and enzyme immunoassay kits for detection of Legionella pneumophila serogroup 1 antigen in both concentrated and nonconcentrated urine samples. Journal of clinical microbiology 1997. link 9 Chang FY, Stout JE, Yu VL. Assessment of enzyme immunoassay versus radioimmunoassay for detection of Legionella pneumophila serogroup 1 antigen in frozen urine specimens. Journal of clinical microbiology 1996. link 10 Helbig JH, Lück PC, Knirel YA, Witzleb W, Zähringer U. Molecular characterization of a virulence-associated epitope on the lipopolysaccharide of Legionella pneumophila serogroup 1. Epidemiology and infection 1995. link 11 Leland DS, Kohler RB. Evaluation of the L-CLONE Legionella pneumophila Serogroup 1 Urine Antigen Latex Test. Journal of clinical microbiology 1991. link 12 Szeto L, Shuman HA. The Legionella pneumophila major secretory protein, a protease, is not required for intracellular growth or cell killing. Infection and immunity 1990. link 13 Ortiz-Roque CM, Hazen TC. Abundance and distribution of Legionellaceae in Puerto Rican waters. Applied and environmental microbiology 1987. link 14 Hindahl MS, Iglewski BH. Isolation and characterization of the Legionella pneumophila outer membrane. Journal of bacteriology 1984. link 15 Engleberg NC, Drutz DJ, Eisenstein BI. Cloning and expression of Legionella pneumophila antigens in Escherichia coli. Infection and immunity 1984. link 16 Fallon RJ, Abraham WH. Polyvalent heat-killed antigen for the diagnosis of infection with Legionella pneumophila. Journal of clinical pathology 1982. link 17 Farshy CE, Klein GC, Feeley JC. Detection of antibodies to legionnaires disease organism by microagglutination and micro-enzyme-linked immunosorbent assay tests. Journal of clinical microbiology 1978. link 18 Hornstra LM, Schijven JF, Waade A, Prat GS, Smits FJC, Cirkel G et al.. Transport of bacteriophage MS2 and PRD1 in saturated dune sand under suboxic conditions. Water research 2018. link 19 Sheng Y, Wang G, Zhao D, Hao C, Liu C, Cui L et al.. Groundwater Microbial Communities Along a Generalized Flowpath in Nomhon Area, Qaidam Basin, China. Ground water 2018. link 20 Salcedo-Sánchez ER, Garrido Hoyos SE, Esteller Alberich MV, Martínez Morales M. Application of water quality index to evaluate groundwater quality (temporal and spatial variation) of an intensively exploited aquifer (Puebla valley, Mexico). Environmental monitoring and assessment 2016. link 21 Albalat GR, Broch BB, Bono MJ. Method modification of the Legipid® Legionella fast detection test kit. Journal of AOAC International 2014. link 22 Rodríguez Albalat G, Bedrina Broch B, Jiménez Bono M. Validation of the Legipid bioalarm Legionella assay. Journal of AOAC International 2012. link 23 Reidt U, Geisberger B, Heller C, Friedberger A. Automated immunomagnetic processing and separation of Legionella pneumophila with manual detection by sandwich ELISA and PCR amplification of the ompS gene. Journal of laboratory automation 2011. link 24 Sani RK, Peyton BM, Dohnalkova A. Comparison of uranium(VI) removal by Shewanella oneidensis MR-1 in flow and batch reactors. Water research 2008. link 25 Armstrong TW, Haas CN. Legionnaires' disease: evaluation of a quantitative microbial risk assessment model. Journal of water and health 2008. link 26 Armstrong TW, Haas CN. Quantitative microbial risk assessment model for Legionnaires' disease: assessment of human exposures for selected spa outbreaks. Journal of occupational and environmental hygiene 2007. link 27 Hwang MG, Katayama H, Ohgaki S. Effect of intracellular resuscitation of Legionella pneumophila in Acanthamoeba polyphage cells on the antimicrobial properties of silver and copper. Environmental science & technology 2006. link 28 Chen DQ, Huang SS, Lu YJ. Efficient transformation of Legionella pneumophila by high-voltage electroporation. Microbiological research 2006. link 29 Newman AP, Pratt CJ, Coupe SJ, Cresswell N. Oil bio-degradation in permeable pavements by microbial communities. Water science and technology : a journal of the International Association on Water Pollution Research 2002. link 30 Helbig JH, Uldum SA, Lück PC, Harrison TG. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. Journal of medical microbiology 2001. link 31 Franzin L, Cabodi D. Comparative evaluation of two commercially available antigen enzyme immunoassays (EIA) for the detection of Legionella pneumophila urinary antigen in frozen non-concentrated urine samples. The new microbiologica 2000. link 32 Roy CR, Berger KH, Isberg RR. Legionella pneumophila DotA protein is required for early phagosome trafficking decisions that occur within minutes of bacterial uptake. Molecular microbiology 1998. link 33 Normaznah Y, Saniah K, Noor Rain A, Norazah A, Azizah MR, Sabiha P. Detection of Legionella pneumophila antigens in patients' sera using monoclonal antibodies. The Malaysian journal of pathology 1998. link 34 Samuel D, Harrison TG, Taylor AG. Detection of Legionella pneumophila serogroup 1 urinary antigen using an enhanced chemiluminescence ELISA. Journal of bioluminescence and chemiluminescence 1990. link 35 Petitjean F, Dournon E, Strosberg AD, Hoebeke J. Isolation, purification and partial analysis of the lipopolysaccharide antigenic determinant recognized by a monoclonal antibody to Legionella pneumophila serogroup 1. Research in microbiology 1990. link90082-2) 36 Wang J, Brown-Schlumpf MS, Brown A, Xie XZ. Seroprevalence of Legionella in Shanxi Province, China. Infection 1988. link 37 Fehrenbach FJ, Horbach I, Ruf B, Shurmann D, Pohle HD. Rapid detection of Legionella antigen in tissues and body fluids. Israel journal of medical sciences 1986. link